April 27, 2020 10:07 AM EDTUpdated 10:22 AM

Regeneron/Sanofi PD-1 trial halted for significant efficacy; Avadel soars on positive narcolepsy data

ENDPOINTS

→ It’s a good news, bad news day for Sanofi and Regeneron. On the same morning their joint Kevzara trial produced disappointing results for Covid …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Regeneron/Sanofi PD-1 trial halted for significant efficacy; Avadel soars on positive narcolepsy data

ENDPOINTS

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Pfizer CEO says opportunities with Trump ‘clearly outweigh’ the risks for pharma

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA approves first drug to treat ultra-rare lipid storage disease

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Re­gen­eron/Sanofi PD-1 tri­al halt­ed for sig­nif­i­cant ef­fi­ca­cy; Avadel soars on pos­i­tive nar­colep­sy da­ta

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Regeneron/Sanofi PD-1 trial halted for significant efficacy; Avadel soars on positive narcolepsy data